EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Rottapharm Biotech shared phase 2 data on CR4056 in chronic pain associated with osteoarthritis. The trial missed its primary endpoint but generated results to encourage Rottapharm that the drug works in patients with a certain phenotype. Release 

> Themis Bioscience began a phase 1 trial of its Zika virus vaccine. Statement 

> Eisai struck a deal with Numab top develop multispecific antibody cancer immunotherapies. Numab will receive an upfront payment plus milestones. Release  

Webinar

CIOs’ Perspectives: Driving Clinical Trial Innovation with a Unified Platform

IT is being challenged with either trying to fix and maintain an already complex system of solution integrations, or exploring driving business impact by unifying its systems under one platform. Attend and learn about the IT benefits to shifting resources away from disparate systems and moving towards a unified platform.

> Novo Holdings and Arix Bioscience co-led a €20 million ($22 million) series A financing in STipe Therapeutics. The funding will support efforts to modulate the STING pathway. Statement 

> Genfit appointed Dean Hum as president of its U.S. operation. Hum is relocating to the U.S. Release  

> Transgene shared clinical data on TG4001 in combination with Merck KGaA and Pfizer’s anti-PD-L1 immunotherapy. Three of the six HPV-positive cancer patients who received the higher dose of therapeutic vaccine TG4001 experienced durable partial responses. Statement 

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.